EUCTR2004-003807-19-GB进行中(未招募)1 期
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study
Merck Sharp & Dohme Ltd0 个研究点目标入组 600 人开始时间: 2005年2月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a.Patient has an LDL-C 130 through 220 mg/dL (3.37 through 5.70 mmol/L) for non-diabetics; LDL-C 100 through 180 mg/dL (2.59 through 4.66 mmol/L) for diabetics, at Visit 2.
- •b.Patient has triglycerides 150 through 500 mg/dL (1.71 through 5.70 mmol/L). [per central laboratory reference ranges] at Visit 2.
- •c.Patient has creatine phosphokinase (CPK) =2 x upper limit of normal (ULN) [per central laboratory reference ranges] at Visit 2.
- •d.Patient has alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =1.5 x upper limit of normal (ULN) [per central laboratory reference ranges] at Visit 2.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a.You are less than 18 years of age or greater than 79 years of age.
- •b.You are pregnant, breastfeeding, or planning to become pregnant during this study.
- •c.You are a woman able to become pregnant and are not willing to use an acceptable method of birth control. You must be willing to use this birth control starting at Visit 1 and continuing 14 days past the last study dose. The study doctor or staff will discuss which methods of birth control are acceptable for this study.
- •d.You are a woman and have taken cyclical hormone birth control or hormone replacement within 8 weeks of Visit 3.
- •e.You have chronic heart failure, uncontrolled irregular heart beats or a history of heart disease. The study doctor or staff will discuss this with you.
- •f.You have diabetes and are taking lipid lowering medication called statins.
- •g.You have a history of cholelithiasis (gallbladder problems) and you have not had your gallbladder removed.
- •h.You have an active liver disease.
- •i.You are HIV positive.
- •j.You have a history of cancer with in the past 5 years (except for skin cancer that has been successfully treated).
- •k.You have taken any investigational drug within 30 days of visit 1.
- •l.You have a history of drug or alcohol abuse with in the past 5 years
- •m.You are not willing to stop drinking large amounts of grapefruit juice (more than a quart) a day.
- •n.You have a know allergy or history of side effects to medicines similar to the drugs used in this study.
研究者
相似试验
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaEUCTR2004-003807-19-ESMerck & Co Inc.600
进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762EUCTR2004-003807-19-ATMerck, Sharp & Dohme600
进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMedDRA version: 7.0Level: LLTClassification code 10027762Mixed hyperlipidemiaEUCTR2004-003807-19-HUMerck & Co., Inc.600
已完成
不适用
The study for beneficial efficacy and safety of ezetimibe in patients with hyper LDL-cholesterolemia associated with diabetes mellitus (DM) including glucose intolerance and non-alcoholic fatty liver disease (NAFLD)non-alcoholic fatty liver disease, diabetes mellitus, hyper LDL-cholesterolemiaJPRN-UMIN000004462Geriatric Medicine, Osaka University Graduate School of Medicine20
尚未招募
2 期
Exploratory survey of the safety and efficacy of endoscopic radiofrequency ablation for malignant biliary strictureMalignant biliary strictureJPRN-UMIN000031601Graduate School of Medicine, Chiba University10
